Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&J
27 Dec 2023
Phase 2AcquisitionPhase 3
Plus, news on the Immunome-Atreca asset deal, Cyclo Therapeutics’ reverse merger, Nestlé buying CDX-7108 from Codexis, Oncternal, Visiox and more.
So long, Applied Molecular Transport:
The stock symbol $AMTI officially became history as Cyclo Therapeutics
completed
its reverse merger and took Applied Molecular Transport’s spot on the Nasdaq under the ticker
$CYTH
. Applied Molecular Transport began hunting for strategic alternatives in
late March
after it halted all R&D activities and laid off the bulk of its staff in the wake of a Phase II flop in ulcerative colitis. The deal with Cyclo was
announced
in September. The company will now focus on a Phase III study of its reformulated drug for Niemann-Pick Disease Type C1.
— Amber Tong
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.